Clinical Trials Logo

Papillomavirus Infections clinical trials

View clinical trials related to Papillomavirus Infections.

Filter by:

NCT ID: NCT06245486 Not yet recruiting - Clinical trials for Human Papillomavirus Infection

Probiotc Lactobacillus Crispatus-M247 (Crispact®) Supplementation in the Sterilization of High-risk Human Papilloma (HPV-HR) Viruses

Start date: February 10, 2024
Phase: N/A
Study type: Interventional

There is growing scientific interest in probiotic supplementation as a possible therapy for clearing the human papillomavirus (HPV) infection and reducing the risk of developement of cervical cancer.

NCT ID: NCT06213051 Not yet recruiting - Clinical trials for Human Papillomavirus Infection

Comparison of Self-collection Using Dry Compared to Wet Swabs for HPV Detection

HPV
Start date: April 1, 2024
Phase:
Study type: Observational

This study will compare the performance of self-collected vaginal swabs, transported without liquid media (dry swabs) and self-collected vaginal swabs, transported in liquid media (wet swabs) for detection of hrHPV DNA to screen for CIN2+ lesions using LBC as the reference standard.

NCT ID: NCT06210854 Not yet recruiting - HPV Infection Clinical Trials

Assessing Jet Administration of pBI-11 for the Treatment of Patients With HPV16/18+

Start date: May 2024
Phase: Phase 2
Study type: Interventional

This is a randomized phase II study. The primary goal of this study is to determine the safety and tolerability of three monthly pBI-11 DNA administrations in each thigh of patients with persistent human papillomavirus 16 (HPV16) and/or human papillomavirus (HPV18+).

NCT ID: NCT06207175 Active, not recruiting - Clinical trials for Human Papillomavirus Infection

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Start date: November 21, 2023
Phase: Phase 3
Study type: Interventional

This Study to Evaluate the Immunogenicity and Safety of Candidate Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli) Administered Intramuscularly in Healthy Female Participants Aged 18 to 45 Years

NCT ID: NCT06206564 Recruiting - Clinical trials for Anal High-grade Squamous Intraepithelial Lesion

Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants

ART-AIN IIB-2
Start date: January 12, 2024
Phase: Phase 2
Study type: Interventional

This is a phase II double blind, placebo-controlled, randomized study of artesunate ointment for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)

NCT ID: NCT06205511 Recruiting - Clinical trials for Human Immunodeficiency Virus

The Prevalence of Oral HPV Infection and Oral Lesions in People Living With HIV

SWISH
Start date: April 1, 2023
Phase:
Study type: Observational

The study will evaluate 300 people living with HIV that attend the Vivent Clinic for HIV care. We will characterize our population and include age, race/ethnicity, sex at birth, tobacco use, alcohol use, other comorbidities, HPV vaccination status, other HPV disease, and lab values such as CD4 count and HIV viral load. We will compare results between participants who are HPV positive and negative. We will also evaluate the relationship between HPV oral infections and lesions and the variables above to better understand possible predictors of HPV infections and lesions.

NCT ID: NCT06199128 Completed - Clinical trials for Human Papillomavirus Infection

Efficacy and Safety of Carboxymethyl Beta-glucan and Policarbophil in HPV Positive Patients

Fix
Start date: September 22, 2022
Phase:
Study type: Observational

Prospective, Controlled, Multicentre, Real Clinical Practice Study. Effectiveness of Carboxymethyl β-Glucan treatment in high-risk HPV+ patients

NCT ID: NCT06177236 Completed - Cervical Cancer Clinical Trials

Clinic or Self-Sampling for Cervical Cancer Screening

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

Objective: The aim of this project was to determine the effect of clinic or self-sampling on attendance, attitudes, and anxiety in cervical cancer screening.

NCT ID: NCT06162676 Not yet recruiting - HPV Infection Clinical Trials

Game-Based Intervention to Promote HPV Vaccination

Start date: December 2023
Phase: N/A
Study type: Interventional

This study will examine the feasibility and acceptability of an innovative game-based intervention designed for families of youth aged 11-14 to promote HPV vaccination; will explore changes in key outcomes and related measures; and will identify factors contributing to or impeding effective implementation in health clinic settings. The intervention and its approach have the potential to reduce health disparities in HPV-associated cancers in youth via low-cost technology and timely intervention.

NCT ID: NCT06137950 Recruiting - HPV Infection Clinical Trials

Interferon Alpha Therapy for Cervical CINI and HPV Infection

Start date: November 7, 2023
Phase: Phase 1
Study type: Interventional

Mongolia is a traditionally nomadic and population is scarce in rural areas. Thus, the medical care service is not sufficient. In 2000, Mongolian government has developed and implemented the millennium project in cooperation with WHO. During the years pap smear analysis of implemented in all rural areas and clinicians, lab technicians have been taught for the cervical cancer screening. However, the project has finished in 2015 and the rural and district hospitals has lost the trained professionals. Still the cervical cancer is in second place after liver cancer in women. The purpose of the study is to identify the type of HPV genotype and to treat the HPV infection by local interferon α2b. Materials and methods: HPV positive patients will be enrolled to the study. HPV genotype will be determined by the PCR in laboratory. Pap smear will be taken and staged by the CIN. Pathological tissue will be taken under colposcopy with acetic acid test. Follow up visit will be done on 10th, 30th days of the treatment. At the end of 90th days of treatment, pap and histology test will be repeated and CIN regression or viral eradication will be evaluated.